Skip to main content
Erschienen in: Rheumatology International 7/2012

01.07.2012 | Case Report

Serious menstrual bleeding associated with use of TNF alpha blocker: two cases

verfasst von: Cemal Bes, Mehmet Soy

Erschienen in: Rheumatology International | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Menstrual disorders associated with the use of TNF alpha blocker have been rarely reported. Herein, we reported two cases aged 31 and 41, presenting with excessive menstrual bleeding occured after adalimumab administration which was subsequently discontinued.
Literatur
1.
Zurück zum Zitat Heijde D, Schiff MH, Sieper J, Kivitz A, Wong RL, Kupper H et al (2009) Adalimumab effectiveness fort he treatment of ankylosing spondylitis is maintained for up to 2 years: long term results from the ATLAS trial. Ann Rheum Dis 68:922–929PubMedCrossRef Heijde D, Schiff MH, Sieper J, Kivitz A, Wong RL, Kupper H et al (2009) Adalimumab effectiveness fort he treatment of ankylosing spondylitis is maintained for up to 2 years: long term results from the ATLAS trial. Ann Rheum Dis 68:922–929PubMedCrossRef
2.
Zurück zum Zitat Scheinfeld N (2008) Menorrhagia and severe menstruel pain related to the use of adalimumab in a psoriatic. J Dermatolog Treat 19(3):188–189PubMedCrossRef Scheinfeld N (2008) Menorrhagia and severe menstruel pain related to the use of adalimumab in a psoriatic. J Dermatolog Treat 19(3):188–189PubMedCrossRef
3.
Zurück zum Zitat Machold KP, Smolen JS (2003) Adalimumab-a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 3:351–360PubMed Machold KP, Smolen JS (2003) Adalimumab-a new TNF-alpha antibody for treatment of inflammatory joint disease. Expert Opin Biol Ther 3:351–360PubMed
4.
Zurück zum Zitat Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di franco M (2007) Biological and clinical effects of anti-TNF alpha treatment. Autoimmun Rev 7(1):35–41PubMedCrossRef Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di franco M (2007) Biological and clinical effects of anti-TNF alpha treatment. Autoimmun Rev 7(1):35–41PubMedCrossRef
5.
Zurück zum Zitat Scheinfeld N (2004) Adalimumab (Humira): a brief review for dermatologists. J Dermatolog Treat 15(6):348–352PubMedCrossRef Scheinfeld N (2004) Adalimumab (Humira): a brief review for dermatologists. J Dermatolog Treat 15(6):348–352PubMedCrossRef
7.
Zurück zum Zitat Kayisli UA, Mahutte NG, Arici A (2002) Uterine chemokines in reproductive physiology and pathology. Am J Reprod Immunol 47(4):213–221PubMedCrossRef Kayisli UA, Mahutte NG, Arici A (2002) Uterine chemokines in reproductive physiology and pathology. Am J Reprod Immunol 47(4):213–221PubMedCrossRef
8.
Zurück zum Zitat Malik S, Day K, Perrault I, Charnock-Jones DS, Smith SK (2006) Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-alpha in menstrual endometrium and effluent in women with menorrhagia. Hum Reprod 21(8):2158–2166PubMedCrossRef Malik S, Day K, Perrault I, Charnock-Jones DS, Smith SK (2006) Reduced levels of VEGF-A and MMP-2 and MMP-9 activity and increased TNF-alpha in menstrual endometrium and effluent in women with menorrhagia. Hum Reprod 21(8):2158–2166PubMedCrossRef
Metadaten
Titel
Serious menstrual bleeding associated with use of TNF alpha blocker: two cases
verfasst von
Cemal Bes
Mehmet Soy
Publikationsdatum
01.07.2012
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 7/2012
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1455-9

Weitere Artikel der Ausgabe 7/2012

Rheumatology International 7/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.